›› 2012, Vol. 32 ›› Issue (2): 226-.doi: 10.3969/j.issn.1674-8115.2012.02.022

• Review • Previous Articles     Next Articles

Update on anti-vascular endothelial growth factor treatment for diabetic macular edema

SUO Yan, LIU Kun, XU Xun   

  1. Department of Ophthalmology, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China
  • Online:2012-02-28 Published:2012-02-28
  • Supported by:

    Shanghai Key Laboratory for Ocular Fundus Diseases Foundation, 07Z22911


Diabetic macular edema (DME) is one of the major causes of visual impairment in patients with diabetes mellitus. The major treatment methods for DME include laser photocoagulation therapy, anti-inflammatory therapy and anti-vascular endothelial growth factor (VEGF) therapy. In recent years, anti-VEGF drugs such as Ranibizumab, Bevacizumab, VEGF-Trap and KH902 have exhibited favorable effects in treatment of DME. The research progress of anti-VEGF therapy for DME is reviewed in this paper, and the efficacy and safety of anti-VEGF therapy are explored.

Key words: diabetic macular edema, laser photocoagulation, anti-inflammatory therapy, anti-vascular endothelial growth factor drug